S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:NUVA

NuVasive Competitors

$48.56
+1.28 (+2.71 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$47.14
Now: $48.56
$48.87
50-Day Range
$43.41
MA: $47.89
$53.50
52-Week Range
$28.55
Now: $48.56
$81.91
Volume754,403 shs
Average Volume897,578 shs
Market Capitalization$2.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.38

Competitors

NuVasive (NASDAQ:NUVA) Vs. ABT, MDT, ISRG, SYK, BDX, and EW

Should you be buying NUVA stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to NuVasive, including Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Risk & Volatility

Abbott Laboratories has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Insider and Institutional Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.9% of NuVasive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Abbott Laboratories and NuVasive's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion5.99$3.69 billion$3.2433.30
NuVasive$1.17 billion2.13$65.23 million$2.4719.66

Abbott Laboratories has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and NuVasive's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
NuVasive-0.84%8.00%3.06%

Analyst Ratings

This is a summary of recent recommendations and price targets for Abbott Laboratories and NuVasive, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
NuVasive19702.35

Abbott Laboratories presently has a consensus target price of $115.3750, suggesting a potential upside of 6.93%. NuVasive has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Given NuVasive's higher possible upside, analysts plainly believe NuVasive is more favorable than Abbott Laboratories.

Summary

Abbott Laboratories beats NuVasive on 12 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Risk & Volatility

Medtronic has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Insider and Institutional Ownership

68.9% of Medtronic shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 0.9% of NuVasive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Medtronic and NuVasive's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.29$4.79 billion$4.5924.80
NuVasive$1.17 billion2.13$65.23 million$2.4719.66

Medtronic has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and NuVasive's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic12.69%9.71%5.30%
NuVasive-0.84%8.00%3.06%

Analyst Ratings

This is a summary of recent recommendations and price targets for Medtronic and NuVasive, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132012.84
NuVasive19702.35

Medtronic presently has a consensus target price of $122.00, suggesting a potential upside of 7.16%. NuVasive has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Given NuVasive's higher possible upside, analysts plainly believe NuVasive is more favorable than Medtronic.

Summary

Medtronic beats NuVasive on 12 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Risk & Volatility

Intuitive Surgical has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Insider and Institutional Ownership

75.1% of Intuitive Surgical shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 0.9% of NuVasive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Intuitive Surgical and NuVasive's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion20.48$1.38 billion$9.9578.43
NuVasive$1.17 billion2.13$65.23 million$2.4719.66

Intuitive Surgical has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intuitive Surgical and NuVasive's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
NuVasive-0.84%8.00%3.06%

Analyst Ratings

This is a summary of recent recommendations and price targets for Intuitive Surgical and NuVasive, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical371202.41
NuVasive19702.35

Intuitive Surgical presently has a consensus target price of $718.2778, suggesting a potential downside of 7.95%. NuVasive has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Given NuVasive's higher possible upside, analysts plainly believe NuVasive is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats NuVasive on 12 of the 14 factors compared between the two stocks.

Stryker (NYSE:SYK) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Profitability

This table compares Stryker and NuVasive's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
NuVasive-0.84%8.00%3.06%

Analyst Ratings

This is a summary of recent recommendations and price targets for Stryker and NuVasive, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
NuVasive19702.35

Stryker presently has a consensus target price of $221.44, suggesting a potential downside of 7.58%. NuVasive has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Given NuVasive's higher possible upside, analysts plainly believe NuVasive is more favorable than Stryker.

Insider and Institutional Ownership

71.0% of Stryker shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 0.9% of NuVasive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Stryker and NuVasive's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion6.05$2.08 billion$8.2629.01
NuVasive$1.17 billion2.13$65.23 million$2.4719.66

Stryker has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Summary

Stryker beats NuVasive on 13 of the 15 factors compared between the two stocks.

NuVasive (NASDAQ:NUVA) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares NuVasive and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NuVasive-0.84%8.00%3.06%
Becton, Dickinson and5.11%13.30%5.60%

Analyst Recommendations

This is a summary of recent ratings and target prices for NuVasive and Becton, Dickinson and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NuVasive19702.35
Becton, Dickinson and07712.60

NuVasive presently has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Becton, Dickinson and has a consensus target price of $280.2857, suggesting a potential upside of 15.46%. Given NuVasive's higher possible upside, analysts clearly believe NuVasive is more favorable than Becton, Dickinson and.

Insider & Institutional Ownership

74.4% of Becton, Dickinson and shares are held by institutional investors. 0.9% of NuVasive shares are held by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares NuVasive and Becton, Dickinson and's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuVasive$1.17 billion2.13$65.23 million$2.4719.66
Becton, Dickinson and$17.12 billion4.11$874 million$10.2023.80

Becton, Dickinson and has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

NuVasive has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Summary

Becton, Dickinson and beats NuVasive on 11 of the 14 factors compared between the two stocks.

NuVasive (NASDAQ:NUVA) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares NuVasive and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NuVasive-0.84%8.00%3.06%
Edwards Lifesciences18.18%29.00%18.10%

Analyst Recommendations

This is a summary of recent ratings and target prices for NuVasive and Edwards Lifesciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NuVasive19702.35
Edwards Lifesciences251302.55

NuVasive presently has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Edwards Lifesciences has a consensus target price of $87.7222, suggesting a potential upside of 2.29%. Given NuVasive's higher possible upside, analysts clearly believe NuVasive is more favorable than Edwards Lifesciences.

Insider & Institutional Ownership

73.8% of Edwards Lifesciences shares are held by institutional investors. 0.9% of NuVasive shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares NuVasive and Edwards Lifesciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuVasive$1.17 billion2.13$65.23 million$2.4719.66
Edwards Lifesciences$4.35 billion12.29$1.05 billion$1.8646.11

Edwards Lifesciences has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

NuVasive has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats NuVasive on 11 of the 14 factors compared between the two stocks.


NuVasive Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$107.90+0.3%$191.24 billion$31.90 billion57.09Increase in Short Interest
Medtronic logo
MDT
Medtronic
2.7$113.85+1.2%$153.04 billion$28.91 billion43.45
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$780.34+2.8%$91.73 billion$4.48 billion88.88Decrease in Short Interest
Heavy News Reporting
Stryker logo
SYK
Stryker
2.0$239.59+2.0%$90.04 billion$14.88 billion56.91Dividend Increase
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$242.76+1.8%$70.41 billion$17.12 billion88.92
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$85.76+2.5%$53.45 billion$4.35 billion68.61
Boston Scientific logo
BSX
Boston Scientific
2.4$34.41+1.7%$49.27 billion$10.74 billion13.18Insider Selling
Baxter International logo
BAX
Baxter International
2.1$78.00+2.2%$39.84 billion$11.36 billion44.32Increase in Short Interest
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$457.15+0.6%$38.99 billion$2.41 billion79.64Insider Selling
Increase in Short Interest
DexCom logo
DXCM
DexCom
1.9$348.03+1.0%$33.42 billion$1.48 billion143.81Insider Selling
ResMed logo
RMD
ResMed
1.7$209.69+1.1%$30.39 billion$2.96 billion49.11Insider Selling
Increase in Short Interest
Hologic logo
HOLX
Hologic
1.9$73.16+0.9%$18.80 billion$3.78 billion17.42Increase in Short Interest
Teleflex logo
TFX
Teleflex
1.8$386.97+2.3%$18.02 billion$2.60 billion38.09Analyst Report
Insider Selling
Insulet logo
PODD
Insulet
1.3$258.88+1.3%$17.07 billion$738.20 million924.60
STERIS logo
STE
STERIS
1.9$193.49+0.4%$16.51 billion$3.03 billion40.23Insider Selling
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$174.66+0.1%$15.96 billion$3.23 billion56.89Analyst Downgrade
Masimo logo
MASI
Masimo
1.4$265.24+1.4%$14.60 billion$937.84 million68.89Analyst Revision
Heavy News Reporting
Abiomed logo
ABMD
Abiomed
1.5$272.61+2.1%$12.32 billion$840.88 million59.91
Hill-Rom logo
HRC
Hill-Rom
2.2$96.43+1.4%$6.44 billion$2.88 billion29.05Decrease in Short Interest
Globus Medical logo
GMED
Globus Medical
1.4$60.75+1.9%$5.99 billion$785.37 million66.03
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$56.39+2.6%$4.75 billion$1.52 billion84.16
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$102.27+1.9%$2.93 billion$955.10 million107.65Insider Selling
Integer logo
ITGR
Integer
2.2$78.61+3.5%$2.58 billion$1.26 billion35.73Increase in Short Interest
AtriCure logo
ATRC
AtriCure
1.5$46.09+4.5%$2.08 billion$230.81 million-40.08Analyst Downgrade
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.25+5.0%$1.45 billion$236.54 million-54.92Heavy News Reporting
Alphatec logo
ATEC
Alphatec
0.8$11.34+3.5%$889.34 million$113.43 million-10.31
CryoLife logo
CRY
CryoLife
2.1$21.57+3.8%$838.15 million$276.22 million-56.76Insider Selling
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.09+2.3%$717.10 million$459.95 million30.91
AngioDynamics logo
ANGO
AngioDynamics
1.3$15.29+7.5%$580.30 million$264.16 million-3.45Analyst Downgrade
Surmodics logo
SRDX
Surmodics
1.5$40.51+4.3%$551.18 million$100.08 million72.34
Accuray logo
ARAY
Accuray
1.9$4.31+6.0%$393.39 million$382.93 million30.79
Invacare logo
IVC
Invacare
1.7$9.09+6.2%$312.86 million$927.96 million-7.39
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$1.17+7.7%$109.48 million$61.30 million-2.60Decrease in Short Interest
This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.